GBG Forschungs GmbH (German Breast Group)

Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study (2015) Hein A, Lambrechts D, Von Minckwitz G, Haeberle L, Eidtmann H, Tesch H, Untch M, et al. Journal article Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)+ (2014) Von Minckwitz G, Loibl S, Untch M, Eidtmann H, Rezai M, Fasching P, Tesch H, et al. Journal article Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial (2014) Von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, Blohmer JU, et al. Journal article Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial (2014) Mueller V, Gade S, Steinbach B, Loibl S, Von Minckwitz G, Untch M, Schwedler K, et al. Journal article Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis (2014) Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, et al. Journal article PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer (2014) Loibl S, Von Minckwitz G, Schneeweiss A, Paepke S, Lehmann A, Rezai M, Zahm DM, et al. Journal article Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma (2014) Loibl S, Volz C, Mau C, Blohmer JU, Costa SD, Eidtmann H, Fasching P, et al. Journal article Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the GeparQuinto study (GBG 44) (2014) Gerber B, Von Minckwitz G, Eidtmann H, Rezai M, Fasching P, Tesch H, Eggemann H, et al. Journal article Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro) (2014) Von Minckwitz G, Rezai M, Fasching P, Huober J, Tesch H, Bauerfeind I, Hilfrich J, et al. Journal article Chemotherapy for 70-Year-old women with breast cancer in Germany: A survey by the German breast group (2013) Barinoff J, Traut A, Bauerschlag DO, Bischoff J, Herr D, Luebbe K, Lueck HJ, et al. Journal article